Figure 1.
Kaplan–Meier curves for cancer recurrence and overall survival of patients treated with and without palonosetron or ramosetron. P-R group patients were treated with ramosetron or palonosetron perioperatively. No P-R group patients were treated without ramosetron and palonosetron perioperatively.
